ArticleBMC infectious diseases2025
Emergence and clinical challenges of ST11-K64 carbapenem-resistant Klebsiella pneumoniae: molecular insights and implications for antimicrobial resistance and virulence in Southwest China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of Klebsiella pneumoniae sequence type 11 but not other virulence factors with patient mortality: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Mortality risk of carbapenem-resistant hypervirulentFrontiers in public health · 2025Pooled it
- Molecular Epidemiology ofMicroorganisms · 2026Article
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Comparative genomic, phenotypic, and clinical characterization of ST11-KL25 and ST11-KL64 hypervirulent carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- Epidemiology, Virulence Factors, and Antibacterial Resistance ofMedicina (Kaunas, Lithuania) · 2026Review
- Plasmid-mediated convergence of multidrug resistance and hypervirulence in community-acquired Klebsiella pneumoniae in Tianjin, China.BMC microbiology · 2026Article
- Protective effects of recombinant depolymerase Dep44 against K64-CRKP-induced pulmonary infection in a murine infection model.BMC microbiology · 2026Article
- O2a O-antigen type and sepsis in invasiveFrontiers in cellular and infection microbiology · 2026Article
- Whole-genome sequencing reveals the genomic characterization and evolution of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Comparative Genomic and Resistance Analysis of ST859-KL19 and ST11 Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Clinical and Genomic Characteristics of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Molecular characteristics and antimicrobial susceptibility of carbapenem-resistantFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn clinical practice, the emergence of ST11-K64 carbapenem-resistant Klebsiella pneumoniae (ST11-K64 CRKP) has become increasingly alarming. Despite this trend, limited research has been conducted to elucidate the clinical and molecular characteristics of these strains.
objectivesThis study aimed to comprehensively investigate the clinical characteristics, antimicrobial resistance patterns, resistance and virulence-associated genes, and molecular epidemiology of ST11-K64 CRKP in Southwest China.
methodsA retrospective analysis was performed on patients infected with carbapenem-resistant Klebsiella pneumoniae (CRKP) in a tertiary care hospital between July 2021 and May 2022. A total of 69 CRKP strains were isolated, with clinical data collected for detailed analysis. Laboratory assessments included antimicrobial susceptibility testing, hypermucoviscosity string testing, genotypic characterization of antimicrobial resistance and virulence genes, and multi-locus sequence typing. Statistical analyses were conducted using SPSS, with significance set at P < 0.05.
resultsAmong the 69 CRKP isolates, 36 strains (52.2%) were identified as ST11-K64 CRKP. Hematological diseases were less associated with ST11-K64 CRKP infection compared to non-ST11-K64 strains (P = 0.012). However, central intravenous catheter use (P = 0.001), mechanical ventilation (P = 0.002), tracheal intubation (P = 0.006), and tracheotomy (P = 0.041) were significantly more common in ST11-K64 CRKP cases. Resistance rates to amikacin (P < 0.001), gentamicin (P = 0.004), tobramycin (P = 0.034), and sulfamethoxazole (P < 0.001) were significantly higher in ST11-K64 CRKP. Additionally, resistance-associated genes such as bla
conclusionOur findings underscore the rising prevalence of ST11-K64 CRKP, characterized by high levels of antimicrobial resistance and the presence of potent resistance and virulence genes. This strain poses a significant clinical and therapeutic challenge, necessitating heightened vigilance, stringent infection control measures, and robust clinical management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.